Global private equity and venture capital news and research

Posts Tagged ‘MPM Capital’

29 August 2014

Venture capital-backed Rhythm files for Nasdaq IPO

nasdaq Venture capital-backed metabolic drug developer Rhythm has filed for an IPO on the Nasdaq exchange.

21 July 2014

NEA, Apple Tree, MPM Capital lead $32m Series B for drug company

capsule-1006559-m New Enterprise Associates, Apple Tree Partners and MPM Capital have helped nervous system disorder specialist Cerecor raise $32m in its Series B first tranche.

19 May 2014

US biopharma Proteon Therapeutics raises $45m Series D

US biopharmaceutical company Proteon Therapeutics has closed a $45m of Series D equity financing, including a $25m tranche to fully fund the first Phase 3 clinical study of its lead product.

18 November 2013

TriVascular raises $40m Series E from new and existing investors

Medical devices startup TriVascular, which is focused on endovascular aortic repair, has raised a $40m Series E round.

9 October 2013

Bay City Capital brings in ex-MPM Capital managing director Ashley Dombkowski

Ashley Dombkowski Bay City Capital Life sciences-focused venture firm Bay City Capital has hired ex-MPM Capital managing director Ashley Dombkowski.

27 August 2013

Syndax Pharmaceuticals raises $26.6m Series B round from healthcare VCs

US-based Syndax Pharmaceuticals has secured a $26.6m Series B financing from investors including healthcare-focused venture capital firms Domain Associates, MPM Capital, Forward Ventures and Russia’s RusnanoMedInvest.

7 August 2013

Corporate venture firms make larger investments than VC peers $

Corporate venture capital firms accounted for a quarter of all venture funding provided in the second quarter and invested significantly more than their peers on average, a study by CB Insights found.

26 July 2013

Venture capital-backed Conatus falls after raising $66m via IPO

Venture capital-backed biotech company Conatus Pharmaceuticals raised $66m via an IPO on the dipped more than 10 per cent in its first day of trading on the Nasdaq exchange after raising $66m via its IPO.

8 May 2013

Venture-backed biopharma Portola eyes $127m Nasdaq IPO

Venture-backed biopharmaceutical company Portola Pharmaceuticals is targeting $127m from its listing on Nasdaq.

7 March 2013

VC firm Novo leads $48m round for Nevro Corp

news_biotech_lrg Venture capital firm Novo Ventures has thrown its support behind Nevro Corp by leading its sizeable $48m Series C funding round, which was also supported by peers Enterprise Associates and Covidien Ventures.

Page 1 of 212

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: Zetland House, 5-25 Scrutton St, London EC2A 4HJ
Content is © AltAssets 2000-2015